See more : Stratos Renewables Corporation (SRNW) Income Statement Analysis – Financial Results
Complete financial analysis of Madrigal Pharmaceuticals, Inc. (MDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Madrigal Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chord Energy Corporation (WLLAW) Income Statement Analysis – Financial Results
- Arcadia Minerals Limited (AM7.AX) Income Statement Analysis – Financial Results
- KARO INVEST a.s. (KARIN.PR) Income Statement Analysis – Financial Results
- LiveXLive Media, Inc. (LIVX) Income Statement Analysis – Financial Results
- Kirin Group Holdings Limited (8109.HK) Income Statement Analysis – Financial Results
Madrigal Pharmaceuticals, Inc. (MDGL)
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Cost of Revenue | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -527.00K | -467.00K | -405.00K | -471.00K | -112.00K | -96.00K | -77.00K | -156.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 272.35M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M | 54.22M | 68.21M | 71.86M | 49.41M | 41.46M | 40.25M | 51.05M | 81.58M | 52.03M | 50.50M | 59.90M | 38.14M | 24.34M | 7.29M | 277.00K |
| General & Administrative | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 11.28M | 7.38M | 5.26M | 0.00 | 124.00K |
| Other Expenses | 0.00 | 0.00 | 273.00K | 100.00K | 0.00 | 200.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Cost & Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Interest Income | 19.58M | 2.19M | 363.00K | 4.33M | 11.02M | 7.67M | 558.00K | 48.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 12.71M | 3.96M | 0.00 | 0.00 | 11.02M | 7.67M | 558.00K | 1.16M | 1.06M | 2.21M | 2.63M | 1.85M | 1.95M | 569.00K | 312.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 662.00K | 673.00K | 516.00K | 738.00K | 1.46M | 1.93M | 2.46M | 2.72M | 3.35M | 3.66M | 2.46M | 1.55M | 1.01M | 47.06M | 0.00 |
| EBITDA | -379.97M | -293.10M | -242.08M | -206.20M | -94.86M | -40.59M | -31.99M | -22.52M | -3.23M | -83.28M | -87.04M | -60.20M | -43.97M | -34.97M | 81.86M | -90.99M | -62.87M | -53.62M | -71.04M | -43.80M | -27.29M | 10.80M | -401.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40,954.42% | -579.75% | -236.20% | 58.40% | -3,479.58% | -8,827.19% | 0.00% | 0.00% | -24,977.46% | -2,124.54% | 0.00% | 0.00% |
| Operating Income | -380.50M | -293.57M | -242.48M | -206.67M | -94.97M | -40.68M | -32.06M | -25.22M | -67.61M | -83.95M | -87.56M | -60.94M | -45.43M | -36.90M | 79.30M | -93.71M | -66.22M | -59.15M | -71.18M | -46.93M | -28.29M | -36.26M | -401.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -41,456.46% | -599.05% | -249.26% | 54.98% | -3,583.48% | -8,911.98% | 0.00% | 0.00% | -27,126.59% | -2,169.79% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.87M | -1.78M | 636.00K | 4.43M | 11.02M | 7.87M | 908.00K | -1.16M | 60.77M | -2.21M | -2.63M | -1.85M | -1.95M | -569.00K | -216.00K | 1.09M | 2.72M | 22.00K | 2.32M | -588.00K | 416.00K | -18.09M | 0.00 |
| Income Before Tax | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -122.08M | -59.13M | -68.86M | -47.52M | -27.88M | -54.35M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -16,430.69% | 0.00% | 0.00% | -27,466.47% | -2,137.88% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.96M | -768.00K | -4.80M | -11.14M | 7.87M | -635.00K | -373.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | -2.72M | -1.88M | -2.32M | 588.00K | -416.00K | -18.20M | 381.00K |
| Net Income | -373.63M | -299.31M | -241.08M | -197.44M | -72.81M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.50M | -57.27M | -68.86M | -45.93M | -27.88M | -36.15M | -381.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -8,545.76% | 0.00% | 0.00% | -26,551.45% | -2,137.88% | 0.00% | 0.00% |
| EPS | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EPS Diluted | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.20 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| Weighted Avg Shares Out | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 968.21K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
| Weighted Avg Shares Out (Dil) | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 974.81K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares soared after the biopharmaceutical firm revealed its live disease drug Rezdiffra has won US Food and Drug Administration (FDA) approval. Shares of the company gained 18.9% at about $290 in early trade on Friday.
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rising higher on Friday after the company got positive news from the Food and Drug Administration (FDA)! The big news here is the FDA granting accelerated approval for Rezdiffra as a treatment for...
Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH
Shares of Madrigal Pharmaceuticals jumped about 30% on Friday after its oral drug became the first treatment to win the health regulator's nod for a fatty liver disease known as non-alcoholic steatohepatitis (NASH).
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are still trying to break into.
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH
Madrigal Pharmaceuticals Inc. on Thursday received the first Food and Drug Administration approval for a drug designed to treat a severe liver disease known as MASH.
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra...
Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Madrigal Pharmaceuticals' drug became the first to win regulatory approval to treat a serious type of fatty liver disease formerly known as non-alcoholic steatohepatitis (NASH) as the race to tap a multi-billion dollar market intensifies.
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to (i) Mardi C. Dier, the Company's new Senior...
Source: https://incomestatements.info
Category: Stock Reports